Gen-Probe (GPRO) Shares Fall as WSJ Says Novartis (NVS) No Longer Pursuing Deal
Tweet Send to a FriendGet Alerts GPRO Hot Sheet
Trade GPRO Now!
After trading in positive territory for most of this morning's session, shares of Gen-Probe (Nasdaq: GPRO) are now down nearly 4 percent following headlines from the WSJ Novartis (NYSE: NVS) is no longer pursuing the company.
Gen-Probe shares last traded at $61.95.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Gen-Probe shares last traded at $61.95.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Bausch & Lomb near deal to sell to Valeant Pharmaceuticals (VRX) - WSJ
- Saks (SKS) said to hire Goldman Sachs for a sale - NY Post
- Valeant (VRX) Continues Deal Hunt; Near to Buy for Bausch & Lomb for $9B
Create E-mail Alert Related Categories
Mergers and Acquisitions, Momentum Movers, Rumors
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
